KR20240146052A - 체중 감소 및 골격근 질량 보존 방법 - Google Patents

체중 감소 및 골격근 질량 보존 방법 Download PDF

Info

Publication number
KR20240146052A
KR20240146052A KR1020247029813A KR20247029813A KR20240146052A KR 20240146052 A KR20240146052 A KR 20240146052A KR 1020247029813 A KR1020247029813 A KR 1020247029813A KR 20247029813 A KR20247029813 A KR 20247029813A KR 20240146052 A KR20240146052 A KR 20240146052A
Authority
KR
South Korea
Prior art keywords
subject
fat
reduction
per day
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247029813A
Other languages
English (en)
Korean (ko)
Inventor
샤하리야 칸
다이앤 조르카스키
프란치스코 포텔
Original Assignee
리부스 파마슈티칼스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 리부스 파마슈티칼스, 인크. filed Critical 리부스 파마슈티칼스, 인크.
Publication of KR20240146052A publication Critical patent/KR20240146052A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1020247029813A 2022-02-07 2023-02-06 체중 감소 및 골격근 질량 보존 방법 Pending KR20240146052A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263307506P 2022-02-07 2022-02-07
US63/307,506 2022-02-07
US202263382456P 2022-11-04 2022-11-04
US63/382,456 2022-11-04
PCT/US2023/062077 WO2023150767A1 (en) 2022-02-07 2023-02-06 Methods of weight loss and preserving skeletal muscle mass

Publications (1)

Publication Number Publication Date
KR20240146052A true KR20240146052A (ko) 2024-10-07

Family

ID=85556813

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247029813A Pending KR20240146052A (ko) 2022-02-07 2023-02-06 체중 감소 및 골격근 질량 보존 방법

Country Status (12)

Country Link
US (1) US20250134864A1 (https=)
EP (1) EP4475841A1 (https=)
JP (1) JP2025505187A (https=)
KR (1) KR20240146052A (https=)
AU (1) AU2023216366A1 (https=)
CA (1) CA3243640A1 (https=)
CL (1) CL2024002341A1 (https=)
GE (1) GEAP202416578A (https=)
IL (1) IL314684A (https=)
JO (1) JOP20240177A1 (https=)
MX (1) MX2024009646A (https=)
WO (1) WO2023150767A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025199516A1 (en) * 2024-03-22 2025-09-25 Board Of Regents, The University Of Texas System Compositions and methods for preserving or increasing lean muscle mass

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3565806T (pt) 2017-01-06 2022-05-19 Rivus Pharmaceuticals Inc Novos derivados de fenilo

Also Published As

Publication number Publication date
US20250134864A1 (en) 2025-05-01
CA3243640A1 (en) 2023-08-10
JOP20240177A1 (ar) 2024-08-04
GEAP202416578A (en) 2024-11-11
WO2023150767A1 (en) 2023-08-10
EP4475841A1 (en) 2024-12-18
IL314684A (en) 2024-10-01
CL2024002341A1 (es) 2025-01-17
MX2024009646A (es) 2024-11-08
AU2023216366A1 (en) 2024-08-15
JP2025505187A (ja) 2025-02-21

Similar Documents

Publication Publication Date Title
US20220152053A1 (en) Methods and compositions for treating various disorders
JP2017513836A (ja) Ｎａｆｌｄおよびｎａｓｈの治療
CN113301889A (zh) Nafld和nash的联合治疗
CN117677395A (zh) 长效glp1/胰高血糖素受体激动剂的剂量方案
TW202114671A (zh) 包含fxr促效劑之治療
TW202114654A (zh) 包含如sglt 1/2抑制劑的sglt抑制劑之治療
KR20240146052A (ko) 체중 감소 및 골격근 질량 보존 방법
TW202313010A (zh) 治療粒線體相關病症之方法
KR20240146053A (ko) 상승된 HbA1c를 갖는 대상체에서의 체중 감소 방법
CN118900692A (zh) HbA1c升高的受试者的体重减轻方法
CN118922187A (zh) 体重减轻和保持骨骼肌量的方法
CN112107581A (zh) 式i化合物在制备治疗肥胖及相关病症的药中的用途
TW202500575A (zh) 具有或不具有體重相關合併症之過重或肥胖成人之治療
CN117881399A (zh) 治疗粒线体相关病症的方法
CN121969358A (zh) 选择性雄激素受体调节剂（sarm）化合物在长期体重管理中的用途
WO2026037397A1 (zh) Glp-1类似物的医药用途
WO2026046202A1 (zh) Glp-1/gip肽或含有其的药物组合物的用途
WO2026021478A1 (zh) Ar降解剂与parp1抑制剂联合用于治疗前列腺癌的方法
JP2018108969A (ja) リンパ浮腫の治療薬
TW202033199A (zh) 化合物ａ與化合物ｂ聯合在製備治療痛風或高尿酸血症的藥物中的用途
CN110038014A (zh) 血红素在改善夜间尿频的药物、食品及保健食品中的应用
EA042686B1 (ru) Способ лечения неалкогольного стеатогепатита

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000